• 1
    Rice D. The economic burden of musculoskeletal conditions, US, 1995. In: PraemerA, FurnerS, RiceD, editors. Musculoskeletal conditions in the US. Rosemont (IL): American Academy of Orthopedic Surgeons; 1999. p. 13962.
  • 2
    Rice D. Estimating the cost of illness. Hyattsville (MD): National Center for Health Statistics; 1966. Health economic series. No. 6.
  • 3
    Cooper B, Rice D. The economic cost of illness revisited. Soc Secur Bull 1979; 39: 2135.
  • 4
    Rice D, Hodgson T, Kopstein A. The economic costs of illness: a replication and update. Health Care Finance Rev 1985; 7: 6180.
  • 5
    Wigle D, Mao Y, Wong T, Lane R. Economic burden of illness in Canada, 1986. Chronic Dis Can 1991; 12: 127.
  • 6
    Yelin E, Callahan L. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum 1995; 38: 135162.
  • 7
    Yelin E, Herrndorf A, Trupin L, Sonneborn D. A national study of medical care expenditures for musculoskeletal conditions: the impact of health insurance and managed care. Arthritis Rheum 2001; 44: 11609.
  • 8
    Dunlop D, Manheim L, Yelin E, Song J, Chang R. The costs of arthritis. Arthritis Rheum 2003; 49: 10113.
  • 9
    Badley E. The economic burden of musculoskeletal disorders in Canada is similar to that for cancer, and may be higher. J Rheumatol 1995; 22: 2046.
  • 10
    Access Economics. Cost of arthritis to the Australian community. The Arthritis Foundation Submission to the Industry Commission Inquiry into Charitable Organizations. Canberra: Arthritis Foundation of Australia; 1994. p. 1422.
  • 11
    Freedman D. Arthritis: the painful challenge. In: Searle Social Research Fellowship Report. Chicago: GD Searle; 1989.
  • 12
    March L, Bachmeier C. Economics of osteoarthritis: a global perspective. Baillieres Clin Rheumatol 1997; 11: 81734.
  • 13
    Levy E, Ferme A, Perocheau D, Bono I. Les couts socio-economiques de l'arthrose en France. Rev Rhum 1993; 60: 63s7s.
  • 14
    Jonsson B, Rehnberg C, Borgquist L, Larsson S. Locomotion status and costs in destructive rheumatoid arthritis. Acta Orthop Scand 1992; 63: 20712.
  • 15
    Eberhardt K, Larsson B, Nived K. Early rheumatoid arthritis: some social, economical, and psychological aspects. Scand J Rheumatol 1993; 22: 11923.
  • 16
    Allaire S, Prashker M, Meenan R. The costs of rheumatoid arthritis. Pharmacoeconomics 1994; 6: 51322.
  • 17
    Prashker M, Meenan R. The total costs of drug therapy for rheumatoid arthritis: a model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995; 38: 31825.
  • 18
    Maclean K, Knight K, Shekelle P, Paulus H, Brook R. Costs attributable to arthritis: implications of costs [abstract]. Arthritis Rheum 1996; 39 Suppl 9: S317.
  • 19
    Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol 1996; 23 Suppl 44: 4751.
  • 20
    Lanes S, Lanza L, Radensky P, Youd R, Meenan R, Walker A, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting. Arthritis Rheum 1997; 40: 147581.
  • 21
    Clarke A, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Saga M, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997; 24: 105160.
  • 22
    Sangha O, Stucki G. Economic impact of rheumatologic disorders. Curr Opin Rheumatol 1997; 9: 1025.
  • 23
    Jaarsveld C, Jacobs J, Schrijvers A, Heurkens A, Haanen H, Bijlsma J. Direct cost of rheumatoid arthritis during the first six years: a cost of illness study. Br J Rheumatol 1998; 37: 83747.
  • 24
    Clarke A, Levinton C, Joseph L, Penrod J, Zowall H, Sibley J, et al. Predicting the short-term direct medical costs incurred by patients with rheumatoid arthritis. J Rheumatol 1999; 26: 106875.
  • 25
    Yelin E, Wanke L. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42: 120918.
  • 26
    Liang M, Larson M, Thompson M, Eaton H, McNamera E, Katz R, et al. Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984; 27: 5229.
  • 27
    Thompson M, Read J, Liang M. Feasibility of willingness to pay measurements in chronic arthritis. Med Decis Making 1984; 4: 195212.
  • 28
    Gabriel S, Crowson C, Campion M, O'Fallon W. Direct medical costs unique to people with arthritis. J Rheumatol 1996; 24: 71925.
  • 29
    Rothfuss J, Mau W, Zeidler H, Brenner M. Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: a literature review. Semin Arthritis Rheum 1997; 26: 7719.
  • 30
    Allaire S, DeNardo B, Szer I, Meenan R, Schaller J. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol 1992; 19: 9525.
  • 31
    Lubeck D, Brown B, Holman H. Chronic disease and health system performance: care of osteoarthritis across three health services. Med Care 1985; 23: 26677.
  • 32
    Gabriel S, Crowson C, O'Fallon W. Costs of osteoarthritis: estimates from a geographically defined population. J Rheumatol 1995; 22 Suppl 43: 235.
  • 33
    Yelin E. The economic impact of osteoarthritis. In: BakerJ, BrandtK, editors. Reappraisal of the management of patients with osteoarthritis. Springfield (NJ): Scientific Therapeutics Information; 1993. p. 103.
  • 34
    Clarke A, Esdaile J, Bloch D, Lacaille D, Danoff D, Fries J. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. Arthritis Rheum 1993; 36: 154859.
  • 35
    Lacaille D, Clarke A, Bloch D, Danoff D, Esdaile J. The impact of disease activity, treatment, and disease severity on short term costs of systemic lupus erythematosus. J Rheumatol 1994; 21: 44853.
  • 36
    Gironimi G, Clarke A, Hamilton V, Danoff D, Bloch D, Fries J, et al. Why health care costs more in the US: comparing health care expenditures between systemic lupus erythematosus patients in Stanford and Montreal. Arthritis Rheum 1996; 39: 97987.
  • 37
    Webster B, Snook S. The cost of compensable low back pain. J Occup Med 1990; 32: 135.
  • 38
    Cohen S. Sample design of the 1996 Medical Expenditure Panel Survey household component. Rockville, MD: Agency for Health Care Policy and Research; 1997. MEPS Methodology Report No. 2. AHCPR Publication No. 97-0027.
  • 39
    Cohen S. Sample design of the 1997 Medical Expenditure Panel Survey household component. Rockville, MD: Agency for Healthcare Research and Quality; 2000. MEPS Methodology Report No. 11. AHRQ Publication No. 01-0001.
  • 40
    Agency for Healthcare Quality and Research. MEPS household component 1996 full year use and expenditure data: public use documentation. Publication No. C6-C11. Rockville, MD: Agency for Healthcare Research and Quality; 1999.
  • 41
    Hoffman C, Rice D, Sung H. Persons with chronic conditions: their prevalence and costs. JAMA 1996; 276: 14739.
  • 42
    Cohen S, DiGaetano R, Goksel H. Estimation procedures in the 1996 Medical Expenditure Panel Survey household component. Rockville, MD: Agency for Health Care Policy and Research; 1999. MEPS Methodology Report No. 5. AHCPR Publication No. 99-0027.
  • 43
    Shah B, Barnwell B, Bieler G. Technical manual: statistical methods and algorithms used in SUDAAN release 7.0. Research Triangle Park (NC): Research Triangle Institute, 1996.
  • 44
    National Institute on Drug Abuse. The economic costs of alcohol and drug abuse in the United States, 1992. Appendix B. Bethesda, MD: National Institutes of Health; 1998. NIH Publication No. 98-4327.
  • 45
    Duan N, Manning W, Morris C, Newhouse J. A comparison of alternative models for the demand for medical care. J Bus Econ Stat 1983; 1: 11526.
  • 46
    Duan N. Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc 1983; 78: 60510.
  • 47
    Impact of arthritis and other rheumatic conditions on the health-care system—United States, 1997. MMWR 1999; 48: 34953.
  • 48
    US Bureau of the Census. Statistical Abstract of the US, 2000. Washington (DC): Dept. of Commerce (US); 2000. p. 451.
  • 49
    Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum 1987; 30: 50712.
  • 50
    Astin J, Pelletier K, Marie A, Haskell W. Complementary and alternative medicine use among elderly persons: one-year analysis of a Blue Shield Medicare supplement. J Gerontol A Biol Sci Med Sci 2000; 55: M49.
  • 51
    Resch K, Hill S, Ernst E. Use of complementary therapies by individuals with 'arthritis'. Clin Rheumatol 1997; 16: 3915.
  • 52
    Lethbridge-Cejku M, Helmick C, Popovic J. Hospitalizations for arthritis and other rheumatic conditions: data from the 1997 National Hospital Discharge Survey. Med Care 2003; 41: 136773.
  • 53
    Hootman J, Helmick C, Schappert S. Magnitude and characteristics of arthritis and other rheumatic conditions on ambulatory Medicare care visits, United States, 1997. Arthritis Rheum 2002; 47: 57181.